	US 12,403,106 B2
	Prophylactic skin treatment for radiation therapy
Derrick C. Wan, Stanford, CA (US); Michael T. Longaker, Stanford, CA (US); and Geoffrey C. Gurtner, Stanford, CA (US)
Assigned to The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Appl. No. 17/778,802
Filed by THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, Stanford, CA (US)
PCT Filed Oct. 20, 2020, PCT No. PCT/US2020/056421 § 371(c)(1), (2) Date May 20, 2022, PCT Pub. No. WO2021/101646, PCT Pub. Date May 27, 2021.
Claims priority of provisional application 62/938,209, filed on Nov. 20, 2019.
Prior Publication US 2022/0409559 A1, Dec. 29, 2022
Int. Cl. A61K 31/16 (2006.01); A61K 9/00 (2006.01); A61P 17/02 (2006.01)

CPC A61K 31/16 (2013.01) [A61P 17/02 (2018.01); A61K 9/0014 (2013.01)]

9 Claims

1. A method of decreasing radiation induced fibrosis, the method comprising:

administering an effective amount of deferoxamine (DFO) transdermally to a region of skin of a subject at a treatment site for a first period of time prior to a radiation treatment;

administering an effective amount of DFO to the region of skin during a second period of time;

administering radiation to the region of skin during the second period of time; and

administering an effective amount of DFO to the region of skin for a third period of time subsequent to the radiation treatment,

wherein the first period of time is 3 days to 21 days,

wherein the second period of time is 5 days to 70 days,

wherein the third period of time is 2 weeks to 8 weeks.